guidanc larg line mse admittedli
street guidanc prudent step reduc
ep volatil plagu share year outlook look
achiev save china structur fundament intact
strong quarter consist messag morgan stanley healthcar
confer organ growth beat mse line
manag commentari morgan stanley healthcar confer see
growth repres bp comp-adjust acceler driven
broad momentum across segment intervent biggest focu
deliv organ growth vs mse repres bp
vs mse driven growth improv target temperatur
manag acut urolog dcb environ continu improv
peripher intervent deliv growth vs mse discuss
medic deliv organ growth vs mse bp
momentum acceler life scienc deliv vs mse
repres bp momentum acceler ep line
mse oper margin vs mse expect in-lin
margin earn bd face fx-driven earn pressur discuss
pleas see exhibit reconcili result vs mse
outlook preview organ growth outlook weaker
earn see driven fx pressur bd guid larg line
organ growth vs mse report ep growth vs mse
fx headwind bp earn bp top line growth
larg explain disconnect guidanc
come surpris investor given manag
vocal currenc impact highlight earn
preview guidanc prudent consid disconnect fx pressur
may emb conservat incom manag tale
two halv organ growth pressur headwind discuss
begin recov estim organ growth vs
growth consequ impact margin expans model
bp expans vs bp earn power
primari consensu disconnect bullish bard thesi
view earn guidanc break new ground us save china may
reflect desir remov type ep volatil frustrat investor
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
year
bridg outlook manag guid cc growth
growth pressur china price md delay
alari roll-out continu dcb pressur peripher
collect repres bp headwind growth impli
growth improv quarterli growth remaind
year alari begin unwind dcb anniversari util
declin top line pressur organ fx explain weaker
ep guid top line pressur impli hit
earn model earn
three issu focu
dcb guidanc includ recoveri dcb
includ btk revenu manag
commentari suggest lutonix share hold steadi rel
medtron pact guid impli quarterli
busi lutonix roughli impli util
unaffect lutonix sale could suggest
conservat highlight y/i declin see
deriv note increment lutonix sale
impli bp upsid bd intervent bp total bd
growth btk suggest pma submiss impli approv
like come back half assumpt
upsid btk like driver
china tender pressur china bulk-ord price pressur basic medic
suppli product individu provinc town particularli around
cathet roughli translat impact double-digit
price hit medic deliveri busi china price
histor steadi strong remain focus
dynam evolv time convinc dynam
repres structur chang china outlook qualiti still matter
alari explain manag highlight bp alari
headwind final softwar updat
fda delay shipment like impact repres signific
complet freez shipment manag confid
repres time issu larg part lost revenu
recov remaind back half year
sustain beyond bard remain equal-weight bd move final
year bard deal model look sustain top line
growth doubl digit underli earn morgan stanley healthcar
confer see manag reiter confid sustain
growth profil beyond bard deal model see upsid
driven capit deploy bd begin tuck-in ii
better expect dcb recoveri earlier expect approv btk
remain equal-weight pt base base case
ebitda last year center view consensu
overestim earn power bard carri return
price target base multipl
base case ebitda reflect premium peer
better pipelin execut drive organ sale acceler bard drive
addit growth high singl digit bd deliv synergi materi
forecast ahead schedul manufactur reloc erp
implement yield greater expect benefit drive oper margin
organ growth sustain becom evid new product
ramp cost program gain traction bard synergi integr
bard integr take longer anticip organ growth slow due
addit eu auster poor pipelin execut dwindl us cash
reserv push buyback poor execut cost initi addit
price pressur limit margin expans see bd multipl contract low
end devic peer group
bard partial price
bd scale medic manag
potenti acceler growth leverag
bard exposur faster growth end market
lower emerg market penetr
bard larg driver margin
improv mix
aggress action cost may
em repres around sale
may drive much third revenu
growth acceler profit doubl
digit growth like requir bd
comfort achiev exceed guidanc
bd estim cost synergi
like floor ceil bard
drive meaning growth acceler
beyond
organ improv bd intern
pipelin on-going updat lutonix
updat ep quantifi ep headwind
tailwind on-going
realiz anticip cost synergi
tax opportun on-going
risk achiev price
integr fall behind schedul
promis synergi fail materi
macro trend get wors competit
pressur em mount
new product launch fail live
million except ep
million
million
incom cont op
net incom common
current portion net invest sales-typ leas
net invest sales-typ leas less
payabl accru expens
defer incom tax
commit conting
depreci amort
net work capit
oper
sale purchas invest
proce discontinu oper
invest
chang short term debt
proce repay long term debt
payment debt
repurchas common
issuanc common stock
financ
net cash provid oper activ
net cash use invest activ
net cash use financ activ
effect exchang rate chang
begin period balanc
end period balanc
